Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 13.8% in October

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 398,900 shares, a growth of 13.8% from the October 15th total of 350,600 shares. Based on an average daily trading volume, of 116,700 shares, the short-interest ratio is presently 3.4 days.

Harvard Bioscience Stock Performance

NASDAQ HBIO traded up $0.01 on Monday, hitting $2.15. 255,230 shares of the company's stock traded hands, compared to its average volume of 117,810. The firm has a market capitalization of $93.78 million, a PE ratio of -6.67 and a beta of 1.31. Harvard Bioscience has a 1-year low of $2.12 and a 1-year high of $5.56. The firm's 50-day moving average price is $2.52 and its two-hundred day moving average price is $2.89. The company has a current ratio of 2.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.52.

Institutional Investors Weigh In On Harvard Bioscience

A number of institutional investors have recently modified their holdings of HBIO. GSA Capital Partners LLP purchased a new position in Harvard Bioscience during the third quarter worth approximately $30,000. Allspring Global Investments Holdings LLC purchased a new position in Harvard Bioscience during the second quarter valued at $31,000. SG Americas Securities LLC purchased a new position in Harvard Bioscience during the third quarter valued at $36,000. Avior Wealth Management LLC grew its position in shares of Harvard Bioscience by 1,118.1% in the third quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 13,373 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Harvard Bioscience during the second quarter worth about $40,000. 80.87% of the stock is currently owned by institutional investors and hedge funds.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.